SCHEMBL4215039

SCHEMBL4215039

CC(C)(C)OC(=O)c1ccc(NC(=O)c2csc3ccccc23)cc1Nc1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 3/20 0.48
MAOB P27338 2/20 0.45
MAPT P10636 5/20 0.44
NFATC1 O95644 1/20 0.43
HTR2C P28335 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4213895 0.85 PIN1 (0.56) PIN1MAOBMAPTNFATC1HTR2C
SCHEMBL14392274 0.75 MAPT (0.48) PIN1MAOBMAPTHDAC3HDAC4
SCHEMBL4223112 0.74 MAPK14 (0.48) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL4215683 0.74 ABCG2 (0.47) MAPTHDAC1HDAC2TP53
SCHEMBL4221744 0.74 ACLY (0.43) MAPTHDAC2F10TP53
SCHEMBL4210312 0.73 AKR1C3 (0.45) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL4213851 0.73 MAPK14 (0.40) MAPTMEN1KMT2AALDH1A1HDAC1
SCHEMBL4215772 0.72 SIRT2 (0.45) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL72623 0.72 PTGDR2 (0.53) PIN1MAOBMAPTNFATC1HTR2C
SCHEMBL4217011 0.71 MPO (0.46) MAPTKMT2ASMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 PIN1 2059/4885MAOB 2181/4885MAPT 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.